Kodiak Sciences to Showcase Innovative KSI-101 at Upcoming Ocular Inflammation Society Congress

Kodiak Sciences Set to Present at IOIS 2025



Kodiak Sciences Inc., a leading player in biopharmaceuticals focused on retinal diseases, has announced its participation in the 2025 Congress of the International Ocular Inflammation Society (IOIS) taking place in Rio de Janeiro, Brazil, on June 27, 2025. The presentation will feature the company’s innovative investigational drug KSI-101, which targets macular edema secondary to inflammation. This significant condition poses substantial risks for vision impairment and is often linked to serious ocular inflammatory conditions.

The Chief Medical Officer, Dr. Pablo Velazquez-Martin, expressed enthusiasm about the upcoming event, noting the importance of engaging with experts in ocular inflammation. The aim is to share insights and push for advancements in care for patients dealing with macular edema caused by inflammation. Macular edema, a condition where fluid accumulates in the retina, can result from various underlying factors such as autoimmune diseases or post-surgical inflammation while often lacking a defined underlying cause.

Traditional treatments for macular edema typically involve steroidal medications. However, prolonged or high-dose steroid usage presents risks of adverse ocular side effects. Dr. Velazquez-Martin commented on the current treatment challenges, stating that both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF) play critical roles in exacerbating macular edema through inflammation. Despite this understanding, there has yet to be an effective intravitreal biologic therapy that simultaneously addresses both mechanisms of the underlying disease process.

At the congress, the Kodiak team, in collaboration with key opinion leaders in the field, will discuss not only the pathophysiology of macular edema caused by inflammation but also the limitations faced by current treatment protocols. The audience can expect to hear real-world case studies demonstrating the need for improved therapeutic options and the promising clinical data surrounding KSI-101. This groundbreaking biopharmaceutical is designed as a first-in-class, bispecific investigational intravitreal biologic that seeks to target both IL-6 and VEGF simultaneously, aiming to substantially enhance patient outcomes and reshape the therapeutic landscape for conditions linked to macular edema secondary to inflammation.

KSI-101 is a high-strength (100 mg/mL) bispecific protein that demonstrates potential in treating mesial conditions of the retina. Kodiak Sciences is currently advancing KSI-101 through its Phase 1b clinical trial named APEX, which is set to evaluate the safety and tolerability of the medication, while seeking to establish two appropriate dosing levels for further Phase 2b/3 studies labeled PEAK and PINNACLE.

As Kodiak Sciences approaches the event date, anticipation builds for the insights and advancements regarding KSI-101 that will be shared at the IOIS meeting. The event promises to serve as a key opportunity to align with leading experts and bring attention to the remarkable potential that KSI-101 holds for improving patient care in the realm of ocular health.

For those interested in following Kodiak’s progress, the presentation will be made available on the company’s website under the “Events and Presentations” section after the summit.

In conclusion, Kodiak Sciences Inc. remains committed to its mission of transforming the treatment for retinal diseases through innovative science and collaboration with the global medical community. The development of KSI-101 exemplifies this commitment, offering hope for effective intervention in macular edema secondary to inflammation and, ultimately, a better quality of life for patients affected by these serious conditions.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.